"
Team:Paris Bettencourt/Project/Overview
From 2013.igem.org
Zmarinkovic (Talk | contribs) |
|||
| (2 intermediate revisions not shown) | |||
| Line 86: | Line 86: | ||
<div class="rightparagraph"> | <div class="rightparagraph"> | ||
<p> | <p> | ||
| - | To defeat tuberculosis, we need new biotechnology. Our work adds 4 new tools to the anti-TB medical armamentarium. <b>Detect</b> - | + | To defeat tuberculosis, we need new biotechnology. Our work adds 4 new tools to the anti-TB medical armamentarium. <b>Detect</b> - a CRISPR-based biosensor delivered by phage and sequence-specific for antibiotic resistance. <b>Target</b> - an <i>E. coli</i> model hosting an essential mycobacterial metabolic pathway that could simplify drug screening. <b>Infiltrate</b> - an <i>E. coli</i> strain capable of entering infected macrophages and lysing mycobacteria. <b>Sabotage</b> - a non-lytic phage that spreads horizontally in a bacterial population and expresses an siRNA to knock down antibiotic resistance. |
</p> | </p> | ||
</div> | </div> | ||
| Line 108: | Line 108: | ||
<p> | <p> | ||
| - | <i>M. tuberculosis</i> grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to <i>E. coli</i>, where | + | <i>M. tuberculosis</i> grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to <i>E. coli</i>, where it is easy to screen for targeted small-molecule inhibitors. |
</p> | </p> | ||
| Line 119: | Line 119: | ||
<p> | <p> | ||
| - | An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, <i>E. coli</i> express | + | An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, <i>E. coli</i> express listeriolysin O (LLO) to enter the macrophage cytosol and Trehalose Dimycolate Hydrolase (TDMH) to degrade the pathogen's membrane. |
</p> | </p> | ||
Latest revision as of 00:27, 29 October 2013
To defeat tuberculosis, we need new biotechnology. Our work adds 4 new tools to the anti-TB medical armamentarium. Detect - a CRISPR-based biosensor delivered by phage and sequence-specific for antibiotic resistance. Target - an E. coli model hosting an essential mycobacterial metabolic pathway that could simplify drug screening. Infiltrate - an E. coli strain capable of entering infected macrophages and lysing mycobacteria. Sabotage - a non-lytic phage that spreads horizontally in a bacterial population and expresses an siRNA to knock down antibiotic resistance.
Detect
Diagnosing antibiotic resistance can improve and accelerate treatment. We propose a phage-delivered, CRISPR-based system that cuts specific DNA sequences and detects the presence of resistance genes due to the resulting DNA damage that is reported with a color output.
Target
M. tuberculosis grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to E. coli, where it is easy to screen for targeted small-molecule inhibitors.
Infiltrate
An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, E. coli express listeriolysin O (LLO) to enter the macrophage cytosol and Trehalose Dimycolate Hydrolase (TDMH) to degrade the pathogen's membrane.
Sabotage
Totally drug-resistant TB (TDR-TB) is an established and growing problem. We have created a phage vector that delivers an siRNA capable of sabotaging drug resistance and restoring sensitivity. By reducing the fitness burden of our construct, we can promote its spread in a population.
+33 1 44 41 25 22/25
team2013@igem-paris.org 
